In fiscal 2025, which ended Dec 27, 2025, Charles River Laboratories International, Inc. generated $737.6 million of cash from operations, up 0.4% from the year before. It spent $219.2 million on capital expenditures. That left free cash flow of $518.5 million. The company returned $360.7 million in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 26, 2026
|
FY 2025
Dec 27, 2025
|
FY 2024
Dec 28, 2024
|
FY 2023
Dec 30, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 25, 2021
|
FY 2020
Dec 26, 2020
|
FY 2019
Dec 28, 2019
|
FY 2018
Dec 29, 2018
|
FY 2017
Dec 30, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
285
-33.3%
|
403
+11.5%
|
362
+15.2%
|
314
+3.4%
|
304
+14.4%
|
266
+13.0%
|
235
+18.6%
|
198
+22.4%
|
162
+23.3%
|
131
+3.6%
|
127
+33.5%
|
| Stock-based compensation |
81
+14.0%
|
71
+1.7%
|
70
-3.0%
|
72
-2.1%
|
74
+3.0%
|
71
+26.9%
|
56
-1.6%
|
57
+21.0%
|
47
+7.6%
|
44
+0.8%
|
44
+8.8%
|
| Operating cash flow |
622
-17.0%
|
738
+0.4%
|
735
+7.4%
|
684
+10.4%
|
620
-18.6%
|
761
|
—
|
—
|
441
+38.7%
|
318
+0.4%
|
317
+3.3%
|
| Investing | |||||||||||
| Capital expenditures |
223
+8.2%
|
219
-5.9%
|
233
-26.9%
|
319
-1.9%
|
325
+41.9%
|
229
+37.4%
|
167
+18.5%
|
141
+0.3%
|
140
+69.9%
|
82
+49.1%
|
55
-12.6%
|
| Investing cash flow |
-462
-140.0%
|
-209
+14.6%
|
-245
+56.5%
|
-563
+7.4%
|
-608
+57.7%
|
-1,438
-139.0%
|
-602
+11.7%
|
-682
+28.6%
|
-955
-1215.7%
|
-73
+89.5%
|
-693
-111.4%
|
| Financing | |||||||||||
| Debt issued |
1,577
+34.1%
|
1,228
+13.5%
|
1,082
+39.3%
|
776
-73.7%
|
2,952
-57.5%
|
6,951
+211.6%
|
2,231
-33.6%
|
3,358
+21.9%
|
2,755
|
—
|
—
|
| Debt repaid |
1,289
-2.2%
|
1,349
-9.7%
|
1,494
+75.4%
|
852
-71.0%
|
2,933
-53.0%
|
6,243
+183.7%
|
2,200
-29.6%
|
3,125
+42.0%
|
2,201
+491.0%
|
372
-43.3%
|
657
|
| Stock buybacks |
324
-10.1%
|
361
+202.6%
|
119
+393.4%
|
24
-37.5%
|
39
-5.1%
|
41
+69.8%
|
24
+32.6%
|
18
+30.6%
|
14
-87.0%
|
107
+771.5%
|
12
-89.6%
|
| Financing cash flow |
-123
+78.1%
|
-537
+2.6%
|
-551
-544.2%
|
-86
-101.7%
|
-42
-106.3%
|
673
+1323.5%
|
47
-79.6%
|
232
-58.4%
|
558
+367.7%
|
-208
-154.8%
|
381
+5346.0%
|
| Change in cash | |||||||||||
| Effect of exchange rate |
3
+88.1%
|
19
+207.7%
|
-17
-317.2%
|
8
-68.6%
|
26
+44.3%
|
18
+2133.0%
|
1
-93.0%
|
11
+219.9%
|
-9
-184.3%
|
11
|
—
|
| Net change in cash |
40
+1747.1%
|
10
+113.2%
|
-79
-282.4%
|
43
+948.4%
|
-5
-138.7%
|
13
+290.5%
|
-7
-116.2%
|
43
+37.9%
|
31
-33.3%
|
46
|
—
|
| Free cash flow |
400
-26.5%
|
518
+3.4%
|
502
+37.3%
|
365
+23.9%
|
295
-44.6%
|
532
|
—
|
—
|
301
+27.8%
|
236
-9.9%
|
262
+7.4%
|
| Per share | |||||||||||
| Free cash flow per share |
8.18
-24.4%
|
10.46
+7.7%
|
9.72
+36.8%
|
7.10
+23.5%
|
5.75
-44.4%
|
10.35
|
—
|
—
|
6.14
+26.6%
|
4.85
-11.1%
|
5.46
|
| Shareholder returns | |||||||||||
| Returned to shareholders |
324
|
361
|
119
|
24
|
39
|
41
|
24
|
18
|
14
|
107
|
12
|
| Share of free cash flow |
81.12%
|
69.56%
|
23.76%
|
6.61%
|
13.11%
|
7.65%
|
—
|
—
|
4.60%
|
45.37%
|
4.69%
|
| Ratios | |||||||||||
| Free cash flow margin |
10.05%
|
12.91%
|
12.39%
|
8.85%
|
7.42%
|
15.03%
|
—
|
—
|
13.29%
|
12.69%
|
15.56%
|
| Capital expenditures to revenue |
5.60%
|
5.46%
|
5.75%
|
7.71%
|
8.17%
|
6.46%
|
5.70%
|
5.36%
|
6.18%
|
4.44%
|
3.29%
|
| Stock-based compensation to revenue |
2.03%
|
1.77%
|
1.73%
|
1.74%
|
1.85%
|
2.02%
|
1.93%
|
2.18%
|
2.09%
|
2.37%
|
2.60%
|
| Cash conversion |
15.49x
|
—
|
33.08x
|
1.44x
|
1.27x
|
1.95x
|
—
|
—
|
1.95x
|
2.58x
|
2.05x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CRL (NYSE)
- Fiscal year ends
- December 27
- Headquarters
- Wilmington, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1100682
- Former names
- CHARLES RIVER LABORATORIES INTERNATIONAL INC (until May 30, 2019); CHARLES RIVER LABORATORIES HOLDINGS INC (until Jan 28, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.